Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451856 | 0.86 | TSHR (0.45) | TSHRALDH1A1CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL8694241 | 0.83 | CA12 (0.36) | TSHRALDH1A1LMNAKMT2ATDP1 | |
| SCHEMBL449195 | 0.81 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPT | |
| SCHEMBL451518 | 0.79 | HCAR2 (0.41) | TSHRALDH1A1LMNATDP1 | |
| SCHEMBL452702 | 0.79 | — | — | |
| SCHEMBL452058 | 0.78 | LMNA (0.38) | TSHRLMNA | |
| SCHEMBL304126 | 0.77 | TSHR (0.48) | TSHRALDH1A1CYP3A4CYP2C9MEN1 | |
| SCHEMBL7417774 | 0.77 | TSHR (0.48) | TSHRALDH1A1CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL2907671 | 0.77 | TSHR (0.34) | TSHRALDH1A1 | |
| SCHEMBL450231 | 0.76 | ATM (0.50) | TSHRALDH1A1CYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| EP-4025253-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar S.A. (ES) | 2022-07-13 | — | — | EP | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR SA (ES) | 2022-06-02 | — | — | US | disclosed |
| US-11224663-B2 | Antibody drug conjugates | PHARMA MAR, S.A. (ES) | 2022-01-18 | — | — | US | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5459148-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0603001-A1 | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO COMPANY LIMITED (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0573218-A2 | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | CD79B, OGFR, CD2 | TSHR 312/4885ALDH1A1 501/4885CYP3A4 629/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | TSHR 1530/4885ALDH1A1 785/4885CYP3A4 1769/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | TSHR 1620/4885ALDH1A1 1158/4885CYP3A4 4050/4885 |
| US-11224663-B2 | Antibody drug conjugates | CD79B, OGFR, CD22 | TSHR 290/4885ALDH1A1 735/4885CYP3A4 573/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | TSHR 1572/4885ALDH1A1 162/4885CYP3A4 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.